The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Emily Curran, University of Cincinnati, Cincinnati, US. We asked, How should we best sequence the new targeted therapies in relapsed B-ALL?
How should we best sequence the new targeted therapies in relapsed B-ALL?
To begin with, Curran discusses the approval of several novel agents such as CAR T-cell therapy, Inotuzumab , and blinatumomab, which have changed the treatment landscape in this field. She expands on what to consider when choosing the appropriate therapy for patients in the relapse setting, including efficacy, disease burden, toxicity, and whether the patient is a stem cell transplant candidate. Curran believes these are exciting times, with the field moving quickly forward which will lead to a better utilisation of novel agents in the future.
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?